Human Diffuse Large B-Cell Lymphoma Peripheral Blood Mononuclear Cells (Newly Diagnosed/Untreated)

Description

Human Diffuse Large B-Cell Lymphoma Peripheral Blood Mononuclear Cells (DLBCL PBMCs) (Newly Diagnosed/Untreated) are derived from the peripheral blood of patients with newly diagnosed but untreated diffuse large B-cell lymphoma (DLBCL). Tumor B cells often harbor chromosomal abnormalities including translocations involving BCL6, MYC, or BCL2 detected by cytogenetic or FISH analysis. They are isolated by density gradient centrifugation, often accompanied by co-isolation of tumor B cells and reactive immune cells (T cells, NK cells, monocytes). They exhibit high expression of B cell markers CD19, CD20, activated B-cell markers MUM1, germinal center markers BCL6, and proliferation markers such as Ki-67. Morphologically, these cells are highly heterogeneous. They carry rearranged immunoglobulin genes (IGH/IGK/IGL), highly express activated B cells or germinal center B cell subtype characteristic molecules (such as MUM1, BCL6), continue to proliferate through pathways such as NF-κB, PI3K/AKT, and secrete factors such as IL-10 and CXCL13 to reshape the immune microenvironment. In clinical and translational settings, these samples contribute to DLBCL progression monitoring, complement diagnostic blood tests large B-cell lymphoma, and enable in-depth evaluation of mononuclear cells in lymphoma study within broader human lymphoma cell research programs.